Literature DB >> 15308122

Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy.

Yi Sun1, Jian Qiao, Chuan-Zhen Lu, Chong-Bo Zhao, Xin-Mei Zhu, Bao-Guo Xiao.   

Abstract

BACKGROUND: CD4(+)CD25(+) regulatory T cells are key controllers of peripheral immunological self-tolerance and suppress various autoimmune diseases in animal models, but few studies have been done to define their roles in myasthenia gravis (MG) so far.
OBJECTIVE: To investigate frequencies and dynamic changes of blood CD4(+)CD25(+) T cells from MG patients.
METHODS: The peripheral blood CD4(+)CD25(+) T cells of 29 MG patients and 23 healthy controls were detected by three-color flow cytometry.
RESULTS: Myasthenic patients with symptomatically uncontrollable disease showed slightly lower percentages of CD4(+)CD25(+) T cells (mean = 3.79 +/- 1.40%; P = 0.12), whereas MG patients with clinically stable disease had significantly increased CD4(+)CD25(+) T cells (mean = 8.45 +/- 1.96%, P = 0.0001), as compared with healthy controls (mean = 4.53 +/- 0.96%). In addition, thymectomized MG patients had significantly higher percentages of CD4(+)CD25(+) T cells (mean = 8.44 +/- 2.39%), as compared with both non-thymectomized MG patients (mean = 5.88 +/- 2.89%, P = 0.038) and healthy controls (P = 0.003).
CONCLUSIONS: Our observations indicate that increased percentages of CD4(+)CD25(+) T cells in MG patients may be related to disease stability and that thymectomy in patients with MG resulted in augmented CD4(+)CD25(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308122     DOI: 10.1016/j.clim.2004.04.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  11 in total

1.  Systemic lupus erythematosus-myasthenia gravis overlap syndrome: Presentation and treatment depend on prior thymectomy.

Authors:  Scott Brian Minchenberg; Geeta Chaparala; Zachary Oaks; Katalin Banki; Andras Perl
Journal:  Clin Immunol       Date:  2018-07-17       Impact factor: 3.969

2.  Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia.

Authors:  Ruolan Liu; Qinghua Zhou; Antonio La Cava; Denise I Campagnolo; Luc Van Kaer; Fu-Dong Shi
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

Review 3.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

4.  Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants.

Authors:  Wen-Hua Xu; Ai-Mei Zhang; Ming-Shan Ren; Xu-Dong Zhang; Fang Wang; Xiu-Cai Xu; Qing Li; Jian Wang; Bang-Sheng Din; Yuan-Bo Wu; Gui-Hai Chen
Journal:  J Clin Immunol       Date:  2012-03-31       Impact factor: 8.317

Review 5.  Regulatory T cells in human autoimmune diseases.

Authors:  Troy R Torgerson
Journal:  Springer Semin Immunopathol       Date:  2006-08-11

Review 6.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

7.  Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.

Authors:  Huan Yang; Yong Zhang; Minghua Wu; Jing Li; Wenbin Zhou; Guiyuan Li; Xiaoling Li; Bo Xiao; Premkumar Christadoss
Journal:  Inflamm Res       Date:  2009-09-19       Impact factor: 4.575

8.  Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Giacomo Minicuci; Raffaella Riso; Laura Peri; Giovanni Scambia; Amelia Evoli
Journal:  J Clin Immunol       Date:  2007-11-14       Impact factor: 8.317

9.  Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis.

Authors:  Min Zhang; Jun Guo; Hongzeng Li; Yongan Zhou; Feng Tian; Li Gong; Xianni Wang; Zhuyi Li; Wei Zhang
Journal:  J Mol Neurosci       Date:  2013-02-10       Impact factor: 3.444

10.  C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.

Authors:  Wei Wang; Monica Milani; Norma Ostlie; David Okita; Rajeev K Agarwal; Rachel R Caspi; Rachel Caspi; Bianca M Conti-Fine
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.